Medicare Carriers Denying Self-Injectable Drug Coverage Despite Mandate
Executive Summary
Medicare's South Carolina carrier is refusing coverage for enoxaparin (Aventis' Lovenox), dalteparin (Pharmacia Fragmin) and interferon (Schering-Plough's Intron A) because they can be self-administered, despite a 1999 Congressional mandate requiring coverage, a South Carolina oncologist reported to a May 18 HCFA Town Hall meeting.
You may also be interested in...
HCFA To Review Medicare Carrier Discretion On Self-Administered Drugs
HCFA is planning to review the amount of discretion that should be allowed to Medicare carriers on the coverage decisions for self-administerable drugs that were available through Medicare before 1997.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011